Caprock Group LLC Has $264,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Caprock Group LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,666 shares of the medical equipment provider’s stock after selling 366 shares during the quarter. Caprock Group LLC’s holdings in Hologic were worth $264,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the third quarter worth approximately $25,000. General Partner Inc. acquired a new stake in Hologic during the fourth quarter worth approximately $26,000. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Cromwell Holdings LLC increased its stake in Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the period. Finally, Covestor Ltd raised its holdings in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several analyst reports. Morgan Stanley reduced their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Evercore ISI decreased their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Mizuho reduced their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Trading Down 10.1 %

NASDAQ HOLX opened at $65.45 on Friday. Hologic, Inc. has a twelve month low of $64.87 and a twelve month high of $84.67. The business’s fifty day moving average is $72.63 and its 200 day moving average is $77.86. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $14.77 billion, a price-to-earnings ratio of 19.65, a price-to-earnings-growth ratio of 2.35 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.